For patients with NYHA class ll–lll obstructive HCM,

The Mechanism of Action of CAMZYOS

CAMZYOS is the first and only approved cardiac myosin inhibitor that targets HCM
at the source1,2

CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state.
This reduces the number of myosin-actin cross-bridges that form.1

See how CAMZYOS works

video icon
CAMZYOS™ (mavacamten) Mechanism of Action Graphic CAMZYOS™ (mavacamten) Mechanism of Action Graphic

Decreasing the number
of excess myosin-actin
cross-bridges:

  • Downward Arrow Icon Reduced dynamic
    LVOT obstruction1
  • Heart Icon Improved cardiac
    filling pressures1
  • Energy Icon Improved energy
    consumption1,2
  • Contracting Heart Icon Reduced cardiac
    contractility2,3

LVOT=left ventricular outflow tract.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

References:

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.
    2020;396(10253):759-769.
  3. Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA. 2018;115(35):E8143-E8152.